MANGOCEUTICALS INC (MGRX) Fundamental Analysis & Valuation

NASDAQ:MGRX • US56270V2051

Current stock price

0.3225 USD
-0.01 (-1.86%)
Last:

This MGRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MGRX Profitability Analysis

1.1 Basic Checks

  • In the past year MGRX has reported negative net income.
  • In the past year MGRX has reported a negative cash flow from operations.
MGRX Yearly Net Income VS EBIT VS OCF VS FCFMGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • MGRX has a worse Return On Assets (-121.68%) than 94.74% of its industry peers.
  • MGRX has a Return On Equity of -127.89%. This is amonst the worse of the industry: MGRX underperforms 86.84% of its industry peers.
Industry RankSector Rank
ROA -121.68%
ROE -127.89%
ROIC N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGRX Yearly ROA, ROE, ROICMGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 60.62%, MGRX belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.
  • MGRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGRX Yearly Profit, Operating, Gross MarginsMGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MGRX Health Analysis

2.1 Basic Checks

  • MGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MGRX has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for MGRX is higher compared to a year ago.
MGRX Yearly Shares OutstandingMGRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
MGRX Yearly Total Debt VS Total AssetsMGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -3.42, we must say that MGRX is in the distress zone and has some risk of bankruptcy.
  • MGRX's Altman-Z score of -3.42 is on the low side compared to the rest of the industry. MGRX is outperformed by 92.11% of its industry peers.
  • MGRX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • MGRX has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. MGRX outperforms 86.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.42
ROIC/WACCN/A
WACC8.9%
MGRX Yearly LT Debt VS Equity VS FCFMGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 0.74 indicates that MGRX may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.74, MGRX is doing worse than 92.11% of the companies in the same industry.
  • MGRX has a Quick Ratio of 0.74. This is a bad value and indicates that MGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of MGRX (0.74) is better than 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
MGRX Yearly Current Assets VS Current LiabilitesMGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MGRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.53% over the past year.
  • The Revenue for MGRX has decreased by -38.15% in the past year. This is quite bad
EPS 1Y (TTM)48.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.84%
Revenue 1Y (TTM)-38.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-40.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGRX Yearly Revenue VS EstimatesMGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 200K 400K 600K

More info and screens

Find the best growth stocksShow best growing peers

0

4. MGRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MGRX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGRX Price Earnings VS Forward Price EarningsMGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGRX Per share dataMGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGRX Dividend Analysis

5.1 Amount

  • No dividends for MGRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MGRX Fundamentals: All Metrics, Ratios and Statistics

MANGOCEUTICALS INC

NASDAQ:MGRX (3/26/2026, 1:21:06 PM)

0.3225

-0.01 (-1.86%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)03-20
Earnings (Next)05-13
Inst Owners16.49%
Inst Owner Change576.02%
Ins Owners11.05%
Ins Owner Change-0.82%
Market Cap4.96M
Revenue(TTM)467.00K
Net Income(TTM)-20.12M
AnalystsN/A
Price TargetN/A
Short Float %12.69%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.63
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.03
BVpS1.02
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -121.68%
ROE -127.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.62%
FCFM N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z -3.42
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-40.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-126.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.79%
OCF growth 3YN/A
OCF growth 5YN/A

MANGOCEUTICALS INC / MGRX Fundamental Analysis FAQ

What is the fundamental rating for MGRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to MGRX.


Can you provide the valuation status for MANGOCEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to MANGOCEUTICALS INC (MGRX). This can be considered as Overvalued.


What is the profitability of MGRX stock?

MANGOCEUTICALS INC (MGRX) has a profitability rating of 1 / 10.


How financially healthy is MANGOCEUTICALS INC?

The financial health rating of MANGOCEUTICALS INC (MGRX) is 2 / 10.